CHMP recommends EU approval of Roche's subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphomaGlobeNewsWire • 09/19/25
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to PipelineZacks Investment Research • 09/18/25
Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total testPRNewsWire • 09/18/25
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio BuyoutInvestors Business Daily • 09/18/25
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASHGlobeNewsWire • 09/18/25
Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experiencePRNewsWire • 09/16/25
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina CongressZacks Investment Research • 09/05/25
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patientsPRNewsWire • 09/05/25
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)GlobeNewsWire • 09/05/25
New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)Business Wire • 09/05/25
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)GlobeNewsWire • 09/04/25
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled HypertensionBusiness Wire • 08/30/25
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertensionGlobeNewsWire • 08/30/25
Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USAGlobeNewsWire • 08/25/25
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North CarolinaBusiness Wire • 08/25/25
Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular CarcinomaBusiness Wire • 08/13/25
Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)GlobeNewsWire • 08/01/25
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)Business Wire • 08/01/25